Allergan Agrees to $15 Million Fine for Failure to Disclose Merger Negotiations During Hostile Bid | Practical Law
The SEC announced a settlement with Allergan, Inc., pursuant to which Allergan would pay a $15 million fine and acknowledge its failure to update its Schedule 14D-9 to disclose the merger negotiations it had begun with Actavis plc and another company while fending off a hostile bid from Valeant Pharmaceuticals International Inc.